6-Chloro-7-deazapurineis commonly used as intermediate in the preparation of pharmaceutically active substances, such as Itacitinib (also named as INCB39110, INCB039110), which is a potent and selective inhibitor of JAK1tyrosine kinase inhibitor in the treatment of rheumatoid arthritis, myelofibrosis, rheumatoid arthritis and plaque psoriasis.
A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. 
 R.Bissonnette, et al, J. Dermatolog. Treat., 2016, 27(4), pp 332-338.
UN 2811 6.1/PG III
1. Product Specification
2. Safety Data Sheet
Available on request.
Please inquire for pricing and availability of this product by writing email firstname.lastname@example.org.